COVID-19 Treatment News: hIVIG does not improve outcomes for adults hospitalized with COVID-19

Trial compared hIVIG plus remdesivir to remdesivir alone

Thursday, January 27, 2022 Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 Scanning electron microscope image of SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the lab. Image captured and colorized at Rocky Mountain Laboratories in Hamilton, Montana. Credit: NIAID A NIAID-funded clinical trial has found that the combination of remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, is not more effective than remdesivir alone for treating adults hospitalized with the disease. The trial also found that the safety of this experimental treatment may vary depending on whether a person naturally generates SARS-CoV-2-neutralizing antibodies before receiving it. The results of the multinational Phase 3 trial were published today in the journal The Lancet. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107